192 related articles for article (PubMed ID: 33188478)
1. Recurrence rate of infantile hemangioma after oral propranolol therapy.
Frongia G; Byeon JO; Mehrabi A; Günther P
Eur J Pediatr; 2021 Feb; 180(2):585-590. PubMed ID: 33188478
[TBL] [Abstract][Full Text] [Related]
2. Predictors of poor response to oral propranolol in infantile hemangiomas.
Hali F; Moubine I; Berrami H; Serhier Z; Othmani MB; Chiheb S
Arch Pediatr; 2023 Oct; 30(7):455-457. PubMed ID: 37394367
[TBL] [Abstract][Full Text] [Related]
3. Exploration of the optimal time to discontinue propranolol treatment in infantile hemangiomas: A prospective study.
Wang L; Wang W; Zhou Z; Li J; Li Z; Lv R; Xu G; Bi J; Huo R
J Am Acad Dermatol; 2024 Apr; 90(4):783-789. PubMed ID: 38159645
[TBL] [Abstract][Full Text] [Related]
4. Propranolol therapy of infantile hemangiomas: efficacy, adverse effects, and recurrence.
Xiao Q; Li Q; Zhang B; Yu W
Pediatr Surg Int; 2013 Jun; 29(6):575-81. PubMed ID: 23519547
[TBL] [Abstract][Full Text] [Related]
5. Rare complication - skin atrophy - after systemic conservative therapy of infantile hemangioma.
Chakhunashvili K; Kvirkvelia E; Todua N; Chakhunashvili DG
BMC Pediatr; 2024 Feb; 24(1):138. PubMed ID: 38395819
[TBL] [Abstract][Full Text] [Related]
6. Management of infantile hemangiomas-experience of a tertiary hospital.
Gomes R; Salazar L; Fraga C; Correia MR; Barbosa-Sequeira J; Fernandes A; Álvares S; Banquart Leitão J; Paiva Coelho M
Eur J Pediatr; 2023 Apr; 182(4):1611-1618. PubMed ID: 36705724
[TBL] [Abstract][Full Text] [Related]
7. Worsening ulceration of infantile hemangioma after initiation or escalation of propranolol.
Meyer-Mueller C; Nicholson C; Polcari I; Boull C; Maguiness S
Pediatr Dermatol; 2022 Mar; 39(2):255-259. PubMed ID: 35178750
[TBL] [Abstract][Full Text] [Related]
8. Nadolol for Infantile Hemangiomas Previously Treated with Propranolol.
Colmenero Sendra M; Del Boz González J; Segura Palacios JM; Valladares Millán I; Eguiluz Solana M; de Troya Martín M
Actas Dermosifiliogr; 2024 Feb; 115(2):215-217. PubMed ID: 37356545
[No Abstract] [Full Text] [Related]
9. Early propranolol treatment of infantile hemangiomas improves outcome.
Giachetti A; Díaz MS; Boggio P; Posadas Martínez ML
An Bras Dermatol; 2023; 98(3):310-315. PubMed ID: 36577593
[TBL] [Abstract][Full Text] [Related]
10. Propranolol and infantile hemangiomas: Outcome from a tricentric study.
Benetton C; Pace MD; De Corti F; Cimador M; Gamba P; Midrio P
J Plast Reconstr Aesthet Surg; 2023 Jan; 76():57-59. PubMed ID: 36513008
[TBL] [Abstract][Full Text] [Related]
11. Monitoring oral propranolol for infantile hemangiomata.
Bar J; Bar-Ilan E; Cleper R; Sprecher E; Samuelov L; Mashiah J
Dermatol Ther; 2022 Nov; 35(11):e15870. PubMed ID: 36177767
[TBL] [Abstract][Full Text] [Related]
12. The impact of propranolol on the growth and development of children with proliferative infantile hemangioma during treatment.
Lin X; Wang T; Liu C; Deng L; Wang Q; Huang L; Gao J; Chen X; Chen S
Medicine (Baltimore); 2023 Jun; 102(23):e33998. PubMed ID: 37335657
[TBL] [Abstract][Full Text] [Related]
13. Does Oral Propranolol Improve the Final Outcome of All Involuted Infantile Hemangiomas? A Matched Retrospective Comparative Study.
Chang SJ; Chang HF; Qiu Y; Chang L; Jin Y; Lin X
Ann Plast Surg; 2022 Aug; 89(2):214-217. PubMed ID: 35502973
[TBL] [Abstract][Full Text] [Related]
14. Infantile hemangiomas: risk factors for complications, recurrence and unaesthetic sequelae.
Mariani LG; Ferreira LM; Rovaris DL; Bonamigo RR; Kiszewski AE
An Bras Dermatol; 2022; 97(1):37-44. PubMed ID: 34848114
[TBL] [Abstract][Full Text] [Related]
15. Early initiation of treatment with oral propranolol for infantile hemangioma improves success rate.
Léauté-Labrèze C; Frieden I; Delarue A
Pediatr Dermatol; 2023 Mar; 40(2):261-264. PubMed ID: 36511888
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cases with infantile hemangioma requiring treatment.
Maraşli H; Acipayam C; Güllü UU; Dinçer S; Dalgiç EF; Karaküçük SN; Yurttutan S
Folia Med (Plovdiv); 2022 Feb; 64(1):67-74. PubMed ID: 35851882
[TBL] [Abstract][Full Text] [Related]
17. Our experience with propranolol for infantile hemangioma.
Wu Y; Zhao P; Song W; Lu W; Dai T; Wang L
Skin Res Technol; 2023 Apr; 29(4):e13310. PubMed ID: 37113082
[TBL] [Abstract][Full Text] [Related]
18. Distribution of problematic localized facial infantile haemangiomas and their response to propranolol: a retrospective cohort study.
Chang L; Chen Q; Zhou L; Chang SJ; Gao W; Yu Z; Chen J; Li H; Qiu Y; Lin X
Clin Exp Dermatol; 2023 Mar; 48(3):193-198. PubMed ID: 36763678
[TBL] [Abstract][Full Text] [Related]
19. Influence of systemic propranolol treatment on the physical development of pediatric patients with infantile hemangiomas.
Dong J; Rong H; Dong Z; Chen A; Wang T; Liu S
Int J Dermatol; 2023 Mar; 62(3):e137-e138. PubMed ID: 35949165
[No Abstract] [Full Text] [Related]
20. A study of 95 infantile hemangiomas treated with propranolol: A potentially efficacious combination with laser therapy.
Yamada-Kanazawa S; Shimada S; Nakayama W; Sawamura S; Nishimura Y; Kajihara I; Makino K; Aoi J; Masuguchi S; Amano F; Fukushima S
Drug Discov Ther; 2023 Mar; 17(1):70-72. PubMed ID: 36843077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
